{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:31:45Z","timestamp":1787164305349,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Innovation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xinn.2026.101305","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:27:36Z","timestamp":1770337656000},"page":"101305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chinese consensus on first-line precision therapy for advanced gastric cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Xiaotian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie\u2019er","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-5356","authenticated-orcid":false,"given":"Xuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-4270","authenticated-orcid":false,"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-6235","authenticated-orcid":false,"given":"Miaozhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xinn.2026.101305_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xinn.2026.101305_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101305_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib4","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2024.42.16_suppl.4040","article-title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 4-year follow-up of CheckMate 649","volume":"42","author":"Elimova","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101305_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib7","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xinn.2026.101305_bib8","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.xinn.2026.101305_bib9","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/j.annonc.2025.05.435","article-title":"Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric\/Gastroesophageal Junction Cancer (GC\/GEJC) in China (SURPASS Study","volume":"36","author":"Liu","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib10","series-title":"CSCO Clinical Practice Guidelines for Gastric Cancer (2025 Edition)","year":"2025"},{"key":"10.1016\/j.xinn.2026.101305_bib11","first-page":"381","article-title":"Chinese Expert Consensus on Detection of Microsatellite Instability in Colorectal Cancer and Other Related Solid Tumors","volume":"34","author":"Yuan","year":"2019","journal-title":"J. Pract. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fonc.2018.00621","article-title":"Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer","volume":"8","author":"Baudrin","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1373\/clinchem.2014.223677","article-title":"Microsatellite instability detection by next generation sequencing","volume":"60","author":"Salipante","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.xinn.2026.101305_bib14","series-title":"Gastric Cancer. Version 5.2024","year":"2024"},{"key":"10.1016\/j.xinn.2026.101305_bib15","article-title":"HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xinn.2026.101305_bib16","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/annonc\/mdt232","article-title":"HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance","volume":"24","author":"Sheng","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.xinn.2026.101305_bib18","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101305_bib19","first-page":"710","article-title":"Expert Consensus on Immunohistochemical Detection of PD-L1 in Solid Tumors (2021 Edition)","volume":"50","year":"2021","journal-title":"Chin. J. Pathol."},{"key":"10.1016\/j.xinn.2026.101305_bib20","first-page":"733","article-title":"Chinese Expert Consensus on Standardization of PD-L1 Immunohistochemical Detection in Non-Small Cell Lung Cancer","volume":"23","author":"Association","year":"2020","journal-title":"Chin. J. Lung Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.646355","article-title":"Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis","volume":"11","author":"Xie","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib22","series-title":"FDA amends pembrolizumab\u2019s gastric cancer indication","year":"2023"},{"key":"10.1016\/j.xinn.2026.101305_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.xinn.2026.101305_bib24","doi-asserted-by":"crossref","first-page":"S877","DOI":"10.1016\/j.annonc.2024.08.1466","article-title":"Overall Survival From Final Analysis of the Phase 3 KEYNOTE-811 Study Evaluating Pembrolizumab Plus Trastuzumab and Chemotherapy in Unresectable or Metastatic HER2+ Gastric\/GEJ Adenocarcinoma","volume":"35","author":"Janjigian","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101305_bib26","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101305_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","article-title":"A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer","volume":"100","author":"Sahin","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib28","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101305_bib29","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101305_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2025.43.4_suppl.454","article-title":"Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric\/gastro-esophageal junction (G\/GEJ) adenocarcinoma from a phase Ib\/II study","volume":"43","author":"Peng","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101305_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.1485","article-title":"Osemitamab (TST001) plus Nivolumab and CAPOX as the First-line Therapy for the Patients with Advanced G\/GEJ Cancer (TranStar102)","volume":"35","author":"Shen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib34","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","article-title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","volume":"30","author":"T\u00fcreci","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib35","first-page":"97","article-title":"Research Progress of Immunotherapy for Epstein-Barr Virus-Associated Gastric Cancer","volume":"63","author":"Zhang","year":"2023","journal-title":"Shandong Med. J."},{"key":"10.1016\/j.xinn.2026.101305_bib36","first-page":"869","article-title":"Consensus of Chinese expert panel on key difficult points of diagnosis and treatment in gastric cancer (2020 edition)","volume":"40","author":"CHINA ANTI-CANCER","year":"2020","journal-title":"Chinese Journal of Practical Surgery"},{"key":"10.1016\/j.xinn.2026.101305_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib38","first-page":"355","article-title":"Research Progress of Epstein-Barr Virus-Associated Gastric Cancer","volume":"19","author":"Liang","year":"2016","journal-title":"Chin. J. Gen. Surg."},{"key":"10.1016\/j.xinn.2026.101305_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12672-022-00479-0","article-title":"PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis","volume":"13","author":"Lima","year":"2022","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib40","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101305_bib41","doi-asserted-by":"crossref","first-page":"S619","DOI":"10.1016\/j.annonc.2023.09.2171","article-title":"A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer","volume":"34","author":"Peng","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004080","article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Bai","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib44","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","article-title":"Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer","volume":"11","author":"Yashiro","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xinn.2026.101305_bib45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib46","first-page":"17","article-title":"Significant function and research progress of biomarkers in gastric cancer","volume":"19","author":"Ye","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.xinn.2026.101305_bib47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41392-025-02193-z","article-title":"PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xinn.2026.101305_bib48","first-page":"1229","article-title":"Research Progress on the Application of Tumor Mutational Burden in Gastric Cancer","volume":"30","author":"Wei","year":"2021","journal-title":"Chin. J. Gen. Surg."},{"key":"10.1016\/j.xinn.2026.101305_bib49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s40425-019-0681-2","article-title":"Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'","volume":"7","author":"Wu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib51","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.annonc.2021.05.803","article-title":"Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma","volume":"32","author":"Shitara","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib52","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-22-0121","article-title":"Association of Tumor Mutational Burden with Efficacy of Pembrolizumab\u00b1Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101305_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.21037\/tcr-21-1601","article-title":"Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma","volume":"11","author":"Zhu","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101305_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib55","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jcp-2023-208865","article-title":"NTRK gene alterations were enriched in hepatoid or enteroblastic differentiation type of gastric cancer","volume":"77","author":"Pu","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.xinn.2026.101305_bib56","article-title":"Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis","volume":"7","author":"Lassen","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib57","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007699","article-title":"Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors","volume":"11","author":"Magahis","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101305_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13880","article-title":"Helicobacter pylori infection and PD-L1 expression in gastric cancer: A meta-analysis","volume":"53","author":"Zhu","year":"2023","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.xinn.2026.101305_bib60","article-title":"Helicobacter pylori and immunotherapy for gastrointestinal cancer","volume":"5","author":"Jia","year":"2024","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2026.101305_bib61","first-page":"943","article-title":"Relationship between Albumin and Neutrophil Combined Prognostic Grading and Prognosis of Advanced Gastric Cancer Treated with Immune Checkpoint Inhibitors","volume":"43","author":"Pan","year":"2022","journal-title":"Academic Journal of Chinese PLA Medical School"},{"key":"10.1016\/j.xinn.2026.101305_bib62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/jgo-23-808","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis","volume":"15","author":"Matsas","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s40001-023-01365-3","article-title":"Mechanisms and biomarkers of immune-related adverse events in gastric cancer","volume":"28","author":"Ding","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.xinn.2026.101305_bib64","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO-24-02463","article-title":"Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer","volume":"43","author":"Kawakami","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib65","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib66","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101305_bib67","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2025.43.4_suppl.398","article-title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 5-year (y) follow-up results from CheckMate 649","volume":"43","author":"Janjigian","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib68","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2025.43.4_suppl.392","article-title":"First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC\/GEJC\/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649","volume":"43","author":"Shen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib69","series-title":"Keytruda (pembrolizumab): assessment report, KEYNOTE-859. EMA\/506795\/2023","year":"2023"},{"key":"10.1016\/j.xinn.2026.101305_bib70","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2023.10.006","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib71","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101305_bib72","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib73","series-title":"FDA ODAC finds limited benefit for checkpoint inhibitors in low PD\u2011L1 gastric cancer. Targeted Oncology","author":"Serani","year":"2024"},{"key":"10.1016\/j.xinn.2026.101305_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103967","article-title":"PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials","volume":"9","author":"Formica","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.xinn.2026.101305_bib75","series-title":"CSCO Annual Meeting","article-title":"First-line Zolbetuximab + mFOLFOX6 in Claudin 18.2 (CLDN18.2)+, HER2-, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Subgroup analysis of Chinese patients in SPOTLIGHT","author":"Liu","year":"2024"},{"key":"10.1016\/j.xinn.2026.101305_bib76","series-title":"CSCO Annual Meeting","article-title":"First-line Zolbetuximab + CAPOX in Claudin 18.2 (CLDN18.2)+, HER2-, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Subgroup analysis of Chinese patients in GLOW","author":"Zhang","year":"2024"},{"key":"10.1016\/j.xinn.2026.101305_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030340","article-title":"Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns","volume":"17","author":"Korpan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xinn.2026.101305_bib78","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.2024.42.16_suppl.4048","article-title":"First-line osemitamab (TST001) plus nivolumab and capox for advanced g\/GEJ cancer (TranStar102): Results of cohort G from a phase I\/IIa study","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib79","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14737167.2024.2378983","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric\/gastroesophageal junction cancer in the Chinese healthcare system","volume":"24","author":"Lang","year":"2024","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.xinn.2026.101305_bib80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17474124.2024.2373730","article-title":"Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective","volume":"18","author":"Li","year":"2024","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xinn.2026.101305_bib81","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231207200","article-title":"Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric\/gastroesophageal junction cancer: a cost-effectiveness analysis","volume":"16","author":"Zhu","year":"2023","journal-title":"Therapeut. Adv. Gastroenterol."},{"key":"10.1016\/j.xinn.2026.101305_bib82","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00432-020-03304-9","article-title":"Artificial intelligence in gastric cancer: a systematic review","volume":"146","author":"Jin","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib83","first-page":"743","article-title":"Application progress of artificial intelligence in the analysis of tumor-tissue histopath-ological biomarkers","volume":"49","author":"Zhang","year":"2022","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101305_bib84","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41392-024-01932-y","article-title":"Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xinn.2026.101305_bib85","article-title":"Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis. Oncol."}],"container-title":["The Innovation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826000524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826000524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:23:28Z","timestamp":1783715008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666675826000524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666675826000524"],"URL":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101305","relation":{},"ISSN":["2666-6758"],"issn-type":[{"value":"2666-6758","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chinese consensus on first-line precision therapy for advanced gastric cancer","name":"articletitle","label":"Article Title"},{"value":"The Innovation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Youth Innovation Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101305"}}